Johnson & Johnson kauft Firefly Bio für 1 Milliarde US-Dollar zur Entwicklung neuer Krebsmedikamente

Johnson & Johnson (JNJ.N) announced on Monday its intention to purchase the biotechnology firm Firefly Bio for $1 billion in cash, aiming to broaden its range of cancer










